by Frank Sorce | Jan 19, 2023 | Press Releases
Expands Expertise in Biologics and Builds Scale in CMC and Quality Consulting Boston, MA, January 19, 2023 – Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and...
by Frank Sorce | Jan 12, 2023 | Press Releases
Rapid Growth Drives the Need for an Investment in Talent January 10, 2023, Boston, MA — Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device...
by Frank Sorce | Aug 21, 2022 | Case Studies
Establishment of a Long-Term Medical Writing Partnership In 2009, IMPACT (now part of Syner-G BioPharma Group) was contracted by a mid-size global pharmaceutical company to prepare 2 Phase 3 clinical study reports (CSRs) for a biologic agent for the treatment of...
by Frank Sorce | Aug 9, 2022 | Case Studies
In 2010, following a referral from another company, IMPACT (now part of Syner-G BioPharma Group) was contacted by a mid-size biopharmaceutical company to assist them with an upcoming NDA for a new chemical entity in the treatment of an orphan condition. Over the next...
by Frank Sorce | Aug 9, 2022 | Case Studies
In 2011, following referral from another company, IMPACT (now part of Syner-G BioPharma Group) was contacted by a small development stage pharmaceutical company located in the United Kingdom to assist them with pre-IND activities for a new chemical entity for the...
